News
09-27-2011, 01:16 AM
The first randomised trial to investigate the use of trastuzumab emtansine (T-DM1) an antibody-guided drug for the initial treatment of HER2- (human epidermal growth factor receptor-2) positive metastatic breast cancer has shown that it makes a significant difference to the time women live without their disease worsening...
More... (http://www.medicalnewstoday.com/releases/235023.php)
More... (http://www.medicalnewstoday.com/releases/235023.php)